Buscar
Congreso SOLACI

Búsqueda de: bleeding

Si no está conforme con los resultados, inténtelo de nuevamente.
Left Atrial Apendix Closure

AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

Atrial fibrillation (AF) is a complex condition in which patients often present with multiple comorbidities, including high...
Dr. Omar Tupayachi -
Ir
Acute coronary syndromes

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as...
Dr. Andrés Rodríguez -
Ir
Antiplatelet

Is it Time to Give Up Aspirin after PCI in High Bleeding Risk Patients? A Critical Analysis of STOPDAPT-3

Short dual antiplatelet treatment (DAPT) has been adopted in high bleeding risk patients to minimize bleeding complications...
Dr. Juan Manuel Pérez -
Ir
Antiplatelet

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a...
Dr. Andrés Rodríguez -
Ir
Antiplatelet

Ultrathin vs Thin-Strut Stents in PCI Patients at High Bleeding Risk

Several in vivo studies have shown that ultrathin stents present lower thrombogenic risk vs. thin-strut stents, which...
Dr. Andrés Rodríguez -
Ir
Left Atrial Apendix Closure

Left Atrial Appendage Occlusion and Early Bleeding

Percutaneous left atrial appendage occlusion (LAAO) is presented as an alternative to chronic oral anticoagulation in patients...
Dr. Omar Tupayachi -
Ir
Acute coronary syndromes

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with...
solaci -
Ir
Coronary disease

SOLACI-SBHCI 2023 | High bleeding and ischemic dilemma: how to evaluate and predict? – Dr. Roxana Mehran

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress. In this case, check the presentation by Dr. Roxana...
solaci -
Ir

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad